85-1410-45　Angiostatin Kringles 1-3, Human, Western Blot Positive Control 100ul　A2294-30B

特徴

• Human K1-3 protein for Western Blot positive control is formulated in SDS-PAGE sample buffer (reduced). This preparation is biologically inactive. It is not suitable for ELISA or other applications where native protein is required.
• Applications:Western Blot: 10ul/lane. Heat once and load. Visualize with appropriate antibodies. This preparation is intended for qualitative purpose and not to serve as standard of known concentration. Angiogenin protein is ~14kD. Store frozen in suitable aliquots. Do not freeze, thaw, or heat repeatedly.
• Activity: Biologically inactive
• Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Angiogenesis accounts for the formation of vasculature into previously avascular organs such as brain and kidney. Angiogenic activity in the adult is required during the normal tissue repair, and for the remodeling of the female reproductive organs (ovulation and placental development). Certain pathological conditions, such as tumor growth and diabetic retinopathy, also require angiogenesis.
• Recent studies have identified several proteolytic fragments or cryptic domains of proteins that act as inhibitors of angiogenesis. These include fragments of plasminogen such as Angiostatin protein (kringles 1-4) and kringles 1-5, C-terminal proteolytic fragment of Collagen XVIII (Endostatin protein), the NC10 domain of collagen 15 (Restin), the C-terminal hemopexin-like domain of MMP-2 (PEX), the N-terminal fragment of prolactin, and the N-terminally truncated platelet factor. Angiostatin protein, a proteolytic fragment of plasminogen, is comprised of the first four kringle regions. It prevents the growth of endothelial cells, and its systemic administration inhibits the growth of primary carcinomas in mice. Kringles 1-3 fragment has a greater inhibitory activity than the Kringles 1-4 fragment. The protease-activated Kringles 1-5 is the most potent plasminogen fragment with over 50-fold greater endothelial cell specific inhibitory activity. Its systemic administration inhibited the growth of fibrosarcoma and significantly reduced neovascularization.
• Applications:Suitable for use in Western Blot. Other applications not tested.
• Recommended Dilution:Western Blot: Load 10ul/lane. Note: SDS may crystallize in cold conditions. Redissolve by warming. It should be heated once prior to loading on gels. If the product has been stored for several weeks, then it may be preferable to add 5ul of fresh 2x sample buffer per 10ul of the A2294-34B solution prior to heating and loading on gels. Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only. For long-term storage, aliquot and store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.